Physician profile
Matthew C Robinson
NPI 1063437838
$4,382.60
in general payments reported to CMS, 2019-2025
21 companies · $811 in 2025
The $811 reported for 2025 was more than what 76% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $419 · 2020: $439 · 2021: $550 · 2022: $544 · 2023: $649 · 2024: $970 · 2025: $811.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,431.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,430.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,347.07 | 2019-2025 | Biktarvy, Veklury |
| Viiv Healthcare Company | $1,074.75 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Astellas Pharma US INC | $318.87 | 2022-2025 | Cresemba |
| Octapharma USA, INC. | $302.79 | 2022-2025 | Panzyga, Octagam Immune Globulin (Human), Cutaquig |
| Merck Sharp & Dohme LLC | $192.53 | 2023-2025 | Zerbaxa, Prevymis, Dificid |
| Insmed, INC. | $152.93 | 2021-2025 | Arikayce, Brinsupri |
| Paratek Pharmaceuticals, INC. | $148.72 | 2020-2025 | Nuzyra |
| Melinta Therapeutics, LLC | $135.08 | 2019-2021 | |
| Abbvie INC. | $113.83 | 2020-2023 | Avycaz, Dalvance |
| Cumberland Pharmaceuticals, INC. | $102.39 | 2023-2025 | Vibativ |
| Emd Serono, INC. | $89.92 | 2021-2023 | Serostim |
| Stryker Corporation | $69.23 | 2020-2025 | 1788 |
| Aimmune Therapeutics, INC. | $53.11 | 2024-2025 | Vowst |
| Allergan, INC. | $47.95 | 2019 | |
| Pfizer INC. | $46.93 | 2023-2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $46.74 | 2024-2025 | Rebyota |
| Shionogi INC | $38.08 | 2021-2025 | Fetroja |
| Janssen Biotech, INC. | $36.03 | 2019 | |
| Theratechnologies INC. | $35.37 | 2020 | |
| Smith+Nephew, INC. | $17.03 | 2021 | |
| Vyera Pharmaceuticals, LLC | $13.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.